$4 Trillion in Cost Savings to U.S. From New Disease-Modifying Alzheimer's Treatments
Myriad Genetics, Inc. reported that a new study has estimated the potential savings to the United States healthcare system, from a disease-modifying Alzheimer's drug, at up to $4.0 trillion. These savings would be for new cases arising between 2010, when the first such drug is estimated by the authors to be available, and 2050, when the number of Alzheimer's disease sufferers could reach its peak.
The study authors note that Alzheimer's disease threatens to become a pandemic and could potentially bankrupt the United States Healthcare system, without new diseases-modifying drugs. The U.S. disease prevalence is expected to grow from the estimated 5.1 million people living with the disease today, to more than 7.7 million by 2030, and 16 million by 2050, which is more than the current total population of New York City, Los Angeles, Chicago and Houston combined.
"These estimates give us the first true glimpse of the potential impact a drug like Myriad's Flurizan could have on the rapidly accelerating costs of treating Alzheimer's disease in this country," said Adrian Hobden, Ph.D., President of Myriad Pharmaceuticals, Inc. "This study calculates the dollar value of a year of life saved from Alzheimer's disease and provides a realistic measure against which payors might make coverage decisions for new therapeutics. The potential savings to the system of delaying the disease for just one year is tremendous."
The study, entitled "Alzheimer's Disease and Cost-Effective Analyses: Ensuring Good Value for Money?" was performed by John Vernon, Ph.D., Department of Finance, University of Connecticut, and National Bureau of Economic Research and colleagues at the University of Connecticut, as well Robert Goldberg, Ph.D., from The Center for Medicine in the Public Interest. The study was sponsored in part by ACT_AD, a coalition of 49 national organizations representing patients, caregivers, providers, consumers, older Americans, researchers and employers seeking to accelerate development of potential cures and treatments for Alzheimer's disease. The coalition is supported in part through educational grants from Wyeth Pharmaceuticals, Elan Corporation and Myriad Genetics, Inc.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
